![]() |
Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in
Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME).
More... |
| All times are GMT -7. The time now is 05:20 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021